Your browser doesn't support javascript.
Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; Yassine, Hadi M; Al-Khatib, Hebah A; Smatti, Maria K; Hasan, Mohammad R; Al-Kanaani, Zaina; Al-Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul-Rahim, Hanan F; Nasrallah, Gheyath K; Al-Kuwari, Mohamed Ghaith; Butt, Adeel A; Al-Romaihi, Hamad Eid; Al-Thani, Mohamed H; Al-Khal, Abdullatif; Bertollini, Roberto; Abu-Raddad, Laith J.
  • Chemaitelly H; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Nagelkerke N; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.
  • Ayoub HH; Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
  • Coyle P; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Tang P; Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
  • Yassine HM; Hamad Medical Corporation, Doha, Qatar.
  • Al-Khatib HA; Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.
  • Smatti MK; Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom.
  • Hasan MR; Department of Pathology, Sidra Medicine, Doha, Qatar.
  • Al-Kanaani Z; Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.
  • Al-Kuwari E; Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Jeremijenko A; Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.
  • Kaleeckal AH; Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Latif AN; Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.
  • Shaik RM; Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Abdul-Rahim HF; Department of Pathology, Sidra Medicine, Doha, Qatar.
  • Nasrallah GK; Hamad Medical Corporation, Doha, Qatar.
  • Al-Kuwari MG; Hamad Medical Corporation, Doha, Qatar.
  • Butt AA; Hamad Medical Corporation, Doha, Qatar.
  • Al-Romaihi HE; Hamad Medical Corporation, Doha, Qatar.
  • Al-Thani MH; Hamad Medical Corporation, Doha, Qatar.
  • Al-Khal A; Hamad Medical Corporation, Doha, Qatar.
  • Bertollini R; Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Abu-Raddad LJ; Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.
J Travel Med ; 2022 Sep 30.
Article in English | MEDLINE | ID: covidwho-2051490
ABSTRACT

BACKGROUND:

The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022.

METHODS:

Three national, matched, retrospective cohort studies were conducted to compare incidence of SARS-CoV-2 infection and COVID-19 severity among unvaccinated persons with a documented SARS-CoV-2 primary infection, to incidence among those infection-naïve and unvaccinated. Associations were estimated using Cox proportional-hazard regression models.

RESULTS:

Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection was 85.5% (95% CI 84.8-86.2%). Effectiveness peaked at 90.5% (95% CI 88.4-92.3%) in the 7th month after the primary infection, but waned to ~ 70% by the 16th month. Extrapolating this waning trend using a Gompertz curve suggested an effectiveness of 50% in the 22nd month and < 10% by the 32nd month. Effectiveness of pre-Omicron primary infection against Omicron reinfection was 38.1% (95% CI 36.3-39.8%) and declined with time since primary infection. A Gompertz curve suggested an effectiveness of < 10% by the 15th month. Effectiveness of primary infection against severe, critical, or fatal COVID-19 reinfection was 97.3% (95% CI 94.9-98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning. Similar results were found in sub-group analyses for those ≥50 years of age.

CONCLUSIONS:

Protection of natural infection against reinfection wanes and may diminish within a few years. Viral immune evasion accelerates this waning. Protection against severe reinfection remains very strong, with no evidence for waning, irrespective of variant, for over 14 months after primary infection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Variants Language: English Journal subject: Communicable Diseases / Public Health Year: 2022 Document Type: Article Affiliation country: Jtm

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Variants Language: English Journal subject: Communicable Diseases / Public Health Year: 2022 Document Type: Article Affiliation country: Jtm